| scholarly article | Q13442814 |
| P2093 | author name string | Sivanesan Dakshanamurthy | |
| Stephen W Byers | |||
| Naiem T Issa | |||
| Oakland J Peters | |||
| P2860 | cites work | Old friends in new guise: repositioning of known drugs with structural bioinformatics | Q37858324 |
| Inverse in silico screening for identification of kinase inhibitor targets. | Q40049537 | ||
| Best of both worlds: on the complementarity of ligand-based and structure-based virtual screening | Q41093798 | ||
| DGIdb: mining the druggable genome | Q41917589 | ||
| No human protein is exempt from bacterial motifs, not even one. | Q42702219 | ||
| Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. | Q42820746 | ||
| Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule | Q43558049 | ||
| Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives | Q46572713 | ||
| Reverse pharmacognosy: application of selnergy, a new tool for lead discovery. The example of epsilon-viniferin | Q46939572 | ||
| Comparison of cancer cell survival triggered by microtubule damage after turning Dyrk1B kinase on and off. | Q51762642 | ||
| Maximizing the therapeutic window of an antimicrobial drug by imparting mitochondrial sequestration in human cells. | Q54368365 | ||
| High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology | Q73851658 | ||
| FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols | Q84074870 | ||
| DrugBank 3.0: a comprehensive resource for 'omics' research on drugs | Q24612505 | ||
| BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities | Q24675698 | ||
| Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome | Q27335598 | ||
| Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia | Q28254349 | ||
| Binding of protein kinase inhibitors to synapsin I inferred from pair-wise binding site similarity measurements | Q28475132 | ||
| Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis | Q28475676 | ||
| Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key | Q28534178 | ||
| Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 | ||
| ZINC: a free tool to discover chemistry for biology | Q29615857 | ||
| A critical assessment of docking programs and scoring functions | Q29616761 | ||
| A small molecule-kinase interaction map for clinical kinase inhibitors | Q29617451 | ||
| Relating protein pharmacology by ligand chemistry | Q29617492 | ||
| Benchmarking sets for molecular docking | Q29619637 | ||
| Real spherical harmonic expansion coefficients as 3D shape descriptors for protein binding pocket and ligand comparisons. | Q30350255 | ||
| Recovering the true targets of specific ligands by virtual screening of the protein data bank | Q30757788 | ||
| Ranking targets in structure-based virtual screening of three-dimensional protein libraries: methods and problems | Q33328263 | ||
| Rapid comparison of protein binding site surfaces with property encoded shape distributions | Q33584321 | ||
| sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins | Q33844638 | ||
| PubChem3D: a new resource for scientists | Q34024530 | ||
| Gaining confidence in high-throughput screening | Q34151663 | ||
| The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells | Q34164315 | ||
| Shape variation in protein binding pockets and their ligands | Q34576866 | ||
| TarFisDock: a web server for identifying drug targets with docking approach | Q34974340 | ||
| Integration of virtual and high-throughput screening | Q34988235 | ||
| On the diversity of physicochemical environments experienced by identical ligands in binding pockets of unrelated proteins | Q35013835 | ||
| Predicting new indications for approved drugs using a proteochemometric method | Q36165369 | ||
| Identification of FDA-approved drugs that computationally bind to MDM2 | Q36252658 | ||
| Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation | Q36458601 | ||
| The Comparative Toxicogenomics Database: update 2013. | Q36491395 | ||
| Synergies of virtual screening approaches | Q37240026 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 784-794 | |
| P577 | publication date | 2015-08-03 | |
| P1433 | published in | Combinatorial Chemistry & High Throughput Screening | Q2985060 |
| P1476 | title | RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions. | |
| P478 | volume | 18 |
| Q35929548 | 1001 Ways to run AutoDock Vina for virtual screening |
| Q93079692 | Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature |
| Q64098902 | Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition |
| Q33599587 | Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors |
| Q42315774 | The purpose of repurposing. |
| Q38981033 | The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma |
Search more.